CANADIAN GUIDELINES FOR THE DEVELOPMENT OF ANTIDEMENTIA THERAPIES - A CONCEPTUAL SUMMARY

被引：41

作者：

MOHR, E

FELDMAN, H

GAUTHIER, S

机构：

[1] UNIV OTTAWA, ROYAL OTTAWA HOSP, MENTAL HLTH RES INST, OTTAWA, ON, CANADA

[2] UNIV BRITISH COLUMBIA, DIV NEUROL, VANCOUVER, BC, CANADA

[3] MCGILL UNIV, MCGILL CTR STUDIES AGING, C5R SECRETARIAT, CONSORTIUM CANADIAN CTR CLIN COGNIT RES, MONTREAL, PQ, CANADA

来源：

CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES | 1995年 / 22卷 / 01期

关键词：

D O I：

10.1017/S0317167100040543

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The magnitude of the problems faced by Canadian society as a result of an aging population has been identified, Perhaps the most important concern related to this greying of Canada is the increasing incidence of dementia and Alzheimer's disease, Therapeutic options for these disorders have been limited to date, Advances in biotechnology and molecular biology will offer novel approaches to treatment. These and the expansion of more traditional therapeutic avenues require guidelines with the aim of optimizing their development.

引用

页码：62 / 71

页数：10

共 137 条

[31]

FELDMAN H, 1993, GERONTOLOGIST, V33, P176

[32] ALZHEIMERS-DISEASE - FOCAL CORTICAL CHANGES SHOWN BY POSITRON EMISSION TOMOGRAPHY [J].